APA (7th ed.) Citation

LR, H., J, T., S, S., F, L., PR, F., KR, M., . . . MR, L. (2024). Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changes. Journal of substance use and addiction treatment, 164, 209391. https://doi.org/10.1016/j.josat.2024.209391

Chicago Style (17th ed.) Citation

LR, Hammerslag, Talbert J, Slavova S, Lei F, Freeman PR, Marks KR, Fanucchi LC, Walsh SL, and Lofwall MR. "Utilization of Long-acting Injectable Monthly Depot Buprenorphine for Opioid Use Disorder (OUD) in Kentucky, Before and After COVID-19 Related Buprenorphine Access Policy Changes." Journal of Substance Use and Addiction Treatment 164 (2024): 209391. https://doi.org/10.1016/j.josat.2024.209391.

MLA (9th ed.) Citation

LR, Hammerslag, et al. "Utilization of Long-acting Injectable Monthly Depot Buprenorphine for Opioid Use Disorder (OUD) in Kentucky, Before and After COVID-19 Related Buprenorphine Access Policy Changes." Journal of Substance Use and Addiction Treatment, vol. 164, 2024, p. 209391, https://doi.org/10.1016/j.josat.2024.209391.